


**REMARKS**

This Preliminary Amendment is being made upon entry of International Application No. PCT/US00/01956 into the U.S. national phase of prosecution. Claim 5 has been amended so that it complies with proper U.S. claim format. Claims 7 and 8 have been added and are directed to specific embodiments of this invention supported in the specification and claims as originally filed. An Abstract has been included on a separate page.

In view of the foregoing, favorable consideration of amended claim 5 and new claims 7 and 8, early examination on the merits and allowance of this application with are respectfully solicited.

A Version with Markings to Show Changes Made to the claims is attached.

Respectfully submitted,

  
Nora Stein-Fernandez  
Attorney for Applicants  
Registration No. 36,689

GLAXOSMITHKLINE  
Corporate Intellectual Property UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5044  
Facsimile (610) 270-5090

n:\nsf\patapps\p50869\preamend for PCT to US.doc

09839904-091001

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

What is claimed is:

5. The method according to [claims 1, 3 and 4] claim 1 wherein the compound is a neurokinin-3 receptor antagonist.

7. The method according to claim 3 wherein the compound is a neurokinin-3 receptor antagonist.

8. The method according to claim 4 wherein the compounds is a neurokinin-3 receptor antagonist.

09889904-091001  
T00T60" +0668860